E
SQZ

Ergoteles’s SQZ Biotechnologies Company SQZ Stock Holding History

Ergoteles’s Portfolio SQZ Stock Details SQZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-64,215
Closed -$47.5K – 1953
2022
Q4 		$47.5K Sell
64,215
-34,744
-35% -$75.9K ﹤0.01% 1298
2022
Q3 		$226K Sell
98,959
-5,364
-5% -$16.1K 0.01% 1114
2022
Q2 		$332K Buy
+104,323
New +$375K 0.01% 1050

Other funds holding SQZ

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's SQZ Position: Q1 2023 in Review

Ergoteles sold out of SQZ Biotechnologies Company (SQZ) in Q1 2023, closing a stake of 64,215 shares — an estimated $47.5K sold.

Ergoteles first reported a position in SQZ in Q2 2022 and held it in 3 quarters. The position peaked at $332K in Q2 2022. 32 funds tracked by Wall St. Rank hold SQZ as of Q1 2023.

  • Ergoteles reported no remaining SQZ Biotechnologies Company position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 64,215 SQZ Biotechnologies Company shares in Q1 2023, an estimated $47.5K.
  • Ergoteles first reported a position in SQZ Biotechnologies Company in Q2 2022 and held it in 3 quarters.
  • Ergoteles's SQZ Biotechnologies Company position peaked at $332K in Q2 2022.
  • 32 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.